Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations

Bing Li, John O. Mascarenhas, Raajit K. Rampal

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Purpose of Review: Although BCR-ABL1-negative myeloproliferative neoplasms (MPN) are chronic, clonal hematopoietic stem cell (HSC) disorders marked by proliferation of one or more myeloid lineages, a substantial proportion of patients transform to acute myeloid leukemia. Leukemic transformation (LT) from a pre-existing MPN carries a dismal prognosis. Here, we review recent genetic, biological, and clinical data regarding LT. Recent Findings: In the last decade, DNA sequencing has revolutionized our understanding of the genomic landscape of LT. Mutations in TP53, ASXL1, EZH2, IDH1/2, and SRSF2 are significantly associated with increased risk of LT of MPNs. Preclinical modeling of these mutations is underway and has yielded important biological insights, some of which have therapeutic implications. Summary: Recent progress has led to the identification of recurrent genomic alterations in patients with LT. This has allowed mechanistic and therapeutic insight into the process of LT. In turn, this may lead to more mechanism-based therapeutic strategies that may improve patient outcomes.

Original languageEnglish
Pages (from-to)588-595
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Volume13
Issue number6
DOIs
StatePublished - 1 Dec 2018

Keywords

  • Gene mutation
  • Leukemic transformation
  • Mouse model
  • Myeloproliferative neoplasms

Fingerprint

Dive into the research topics of 'Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations'. Together they form a unique fingerprint.

Cite this